The Board of Directors of Artemis Medicare Services today approved the company’s audited financial results for the 4th quarter (Jan to Mar) and 12M (Apr to Mar) for the financial year 2024 – 25.

For the quarter ended March 31, 2025 Artemis Medicare Services, on a consolidated level, registered a gross revenue of Rs 2,521 Million, an increase of 7.0 per cent over the same period last fiscal. For the fiscal year (April – March), the company’s gross revenue closed at Rs 9,819 Million, an increase of 6.5 per cent over the same period last fiscal. The Board of Directors have recommended a final dividend of 45 per cent per Equity Share of face value of Re 1 each for FY25, subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.

Commenting on the company’s performance, Onkar Kanwar, Chairman, Artemis Medicare Services said “Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.

To fuel our next growth phase, we raised Rs 3.30 billion from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies. As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India’s most trusted and respected healthcare brands.”